-
Nuwellis ( NASDAQ: NUWE ) anticipates Q4 revenue to be ~$2.3M, representing an increase of 42% Y/Y vs consensus of $2.21M .
-
The fourth quarter revenue by segment was led by Pediatrics, followed by Heart Failure and Critical Care, which increased ~92%, 47%, and 24% Y/Y, respectively.
-
FY22 revenue expected to be ~$8.5M, representing an increase of 8% Y/Y vs consensus of $8.41M.
-
“Preliminary 2022 revenue growth of approximately 42% for the fourth quarter and 8% for the full year demonstrates continued meaningful progress on the execution of our key strategic initiatives, as the expansion of our field sales team and clinical education specialists, bolstered by our market penetration initiatives and growing body of clinical evidence, drove strong sales momentum in the fourth quarter. We are committed to making the Aquadex SmartFlow® system the standard of care for patients with fluid overload who are not responsive to diuretics, driving strong growth in 2023 and beyond,” said Nestor Jaramillo, President and CEO of Nuwellis.
For further details see:
Nuwellis guides preliminary Q4 and FY22 revenue slightly above consensus